We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has CRISPR THERAPTC (CRSP) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is CRISPR THERAPTC (CRSP - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CRISPR THERAPTC is one of 763 companies in the Medical group. The Medical group currently sits at #12 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CRSP is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for CRSP's full-year earnings has moved 7.81% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, CRSP has gained about 152.73% so far this year. In comparison, Medical companies have returned an average of 1.65%. This means that CRISPR THERAPTC is outperforming the sector as a whole this year.
Looking more specifically, CRSP belongs to the Medical - Biomedical and Genetics industry, which includes 282 individual stocks and currently sits at #163 in the Zacks Industry Rank. On average, this group has lost an average of 3.23% so far this year, meaning that CRSP is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on CRSP as it attempts to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has CRISPR THERAPTC (CRSP) Outpaced Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is CRISPR THERAPTC (CRSP - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CRISPR THERAPTC is one of 763 companies in the Medical group. The Medical group currently sits at #12 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CRSP is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for CRSP's full-year earnings has moved 7.81% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, CRSP has gained about 152.73% so far this year. In comparison, Medical companies have returned an average of 1.65%. This means that CRISPR THERAPTC is outperforming the sector as a whole this year.
Looking more specifically, CRSP belongs to the Medical - Biomedical and Genetics industry, which includes 282 individual stocks and currently sits at #163 in the Zacks Industry Rank. On average, this group has lost an average of 3.23% so far this year, meaning that CRSP is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on CRSP as it attempts to continue its solid performance.